Carisma, a Philadelphia-based biotech company, is undergoing significant restruc...
BioAge Labs, a recent success in the biotechnology IPO market, has made a surpri...
As part of a first-line treatment for patients with inoperable pancreatic adenoc...
Novartis has paid out $1 billion upfront for worldwide rights to PTC Therapeutic...
Likely to be effective next year, GE HealthCare will assume full control of Niho...
A new independent survey of senior US pharma regulatory professionals suggests t...
Merck has released that its drug, Winrevair, reduced the risk of death in patien...
A late-stage study testing the efficacy of Biohaven’s taldefgrobep alpha against...
A bispecific antibody has emerged in the HER2 arena, exhibiting a different prof...
Hailed as the first oral peptide designed to selectively block IL-23, Johnson & ...
Incyte faced severe difficulties just a few months after purchasing Escient Phar...
The Canada-based biotechnology company Cybin has announced the results of a Phas...
Roche has entered a groundbreaking deal worth more than $1.8B with Flare Therape...
Maryland-based biotech Novavax experienced a clinical hold on its late-stage tri...
After the FDA approves Johnson & Johnson MedTech’s Varipulse technology for the ...
AbbVie saw its valuation drop by around $40 billion following disappointing resu...
